Ginkel, C.V.; Martens, F.; Scholtes, M.; Heesakkers, J.; Janssen, D.A.W. Quality of Life and Treatment Modalities in Patients with Interstitial Cystitis: The Patients’ Perspective. Healthcare2024, 12, 466.
Ginkel, C.V.; Martens, F.; Scholtes, M.; Heesakkers, J.; Janssen, D.A.W. Quality of Life and Treatment Modalities in Patients with Interstitial Cystitis: The Patients’ Perspective. Healthcare 2024, 12, 466.
Ginkel, C.V.; Martens, F.; Scholtes, M.; Heesakkers, J.; Janssen, D.A.W. Quality of Life and Treatment Modalities in Patients with Interstitial Cystitis: The Patients’ Perspective. Healthcare2024, 12, 466.
Ginkel, C.V.; Martens, F.; Scholtes, M.; Heesakkers, J.; Janssen, D.A.W. Quality of Life and Treatment Modalities in Patients with Interstitial Cystitis: The Patients’ Perspective. Healthcare 2024, 12, 466.
Abstract
Background: Quality of life (QoL) in IC/BPS patients is an evidence gap in guidelines, because studies are limited and outdated. Therefore, guidelines might not reflect the current situation accurately, and no possible improvements in QoL of these patients. Secondly, guidelines suggest multimodal approach in therapy, however unknown is how the efficacy of these therapies are perceived by the patient themselves. The aim of this study is to investigate the perception of IC/BPS patients on their QoL and to determine which treatments they received and how they evaluate the efficacy of these various (alternative) therapies.Methods: Quantitative retrospective database study in IC/BPS patients, compiled of existing patient survey data (n=217) from July 2021. Results: The QoL of patients is affected significantly by IC/BPS. This is evident from the substantial self-reported impact by patients, the various affected domains on EQ-5D 5L. The QoL was not negatively affected by delayed diagnosis, but there were differences between female and males. Secondly, there was the wide array of (alternative) treatments utilized, although some have doubtful results and high dropout rates. Conclusion: QoL is considerably impaired in IC/BPS patients. Coagulation therapy and intravesical GAG therapy were most appreciated treatments. The diverse responses and adherence to various treatments warrant a personalized approach (phenotype-oriented therapy). To achieve improvement in the QoL, it is important to incorporate the patient’s perspective in treatment guidelines.
Keywords
interstitial cystitis; bladder pain syndrome; Quality of Life; Therapies; Lifestyle
Subject
Medicine and Pharmacology, Urology and Nephrology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
